Crossing the ANVISA Gate: MediPharm Unlocks Brazil's $2.5B Cannabis Market

TORONTO, Nov. 10, 2026 — For years, the global cannabis industry has been caught in a tug-of-war between agricultural commoditization and pharmaceutical precision. As domestic markets in North America grapple with oversupply and margin compression, the real battleground for sustainable profitability has shifted overseas. Today, MediPharm Labs Corp. fired a significant shot in that global campaign, announcing the commercial launch of a full-spectrum CBD oral oil in Brazil alongside local pharmaceutical partner Alko do Brasil Indústria e Comércio Ltda.

The launch is not merely a new product announcement; it is a masterclass in regulatory strategy. Brazil represents Latin America’s largest economy and, by many estimates, one of its most lucrative medical cannabis markets. Yet, it is famously guarded by one of the world’s most formidable regulatory gatekeepers: the Brazilian Health Regulatory Agency, known as ANVISA.

By successfully navigating ANVISA’s labyrinthine requirements to secure a Sanitary Authorization, MediPharm is demonstrating how stringent Good Manufacturing Practices (GMP) can serve not just as a compliance metric, but as a powerful economic moat.

The Regulatory Moat: Why GMP is the Price of Admission

Brazil’s approach to medical cannabis is strictly clinical. Following the implementation of ANVISA’s Resolution 327 in 2019, the country established a framework that aggressively prioritizes pharmaceutical dosage forms—such as meticulously measured oral oils and sublingual formulations—over the dried cannabis flower that dominates the Canadian and U.S. markets.

More importantly, ANVISA does not grade on a curve. Foreign manufacturers seeking to export to Brazil cannot simply present a domestic license and expect entry. They must hold a valid, ANVISA-issued pharmaceutical GMP certificate specifically for the relevant production line and dosage form. The agency does not accept equivalent foreign documentation, forcing companies to undergo rigorous direct audits.

MediPharm’s facility in Barrie, Ontario, achieved this coveted ANVISA GMP certification in early 2024, laying the critical groundwork for today’s commercial launch. Furthermore, Brazilian regulations mandate that every imported lot must undergo secondary quality control testing upon arrival in Brazil, even if it was exhaustively tested in its country of origin.

"This launch represents the continued execution of MediPharm’s international growth strategy and further validates our position as a trusted global supplier of cannabinoid-based products manufactured under pharmaceutical quality standards," said Greg Hunter, Chief Executive Officer of MediPharm Labs.

Hunter further noted the duality of the Brazilian landscape: "Brazil is one of the fastest-growing medical cannabis markets in the world, but it is also one of the most difficult to access from a regulatory perspective. Successfully supporting an ANVISA Sanitary Authorization demonstrates the strength of our pharmaceutical manufacturing capabilities."

Sizing the Prize: Inside a C$2.58 Billion Opportunity

The financial incentive for scaling this regulatory wall is immense. Market intelligence firm Kaya Mind estimates the potential size of Brazil’s medical cannabis market at approximately C$2.58 billion (R$9.49 billion). This projection is grounded in explosive real-world demand. In 2022 alone, Brazil witnessed a 480% increase in medical cannabis prescriptions, a trajectory that has continued to climb as local physicians become more comfortable with cannabinoid therapies.

Commercialization in Brazil operates entirely through traditional healthcare infrastructure. Products are dispensed exclusively in pharmacies and require specialized medical prescriptions—a blue "Type B" form for products with less than 0.2% THC, and a yellow "Type A" form for anything exceeding that threshold. Furthermore, ANVISA prohibits pharmacists from substituting or interchanging prescribed cannabis products, meaning brand loyalty and physician education are paramount to capturing market share.

Alko do Brasil, a company with deep roots in the Brazilian healthcare sector dating back to 1988, is tasked with this crucial on-the-ground commercialization. By acting as the local authorization holder and distributor, Alko bridges the gap between MediPharm’s Canadian manufacturing floor and the Brazilian patient.

"Alko has seized the opportunity and sees a bright future for their investment in Brazilian cannabis," said Alko’s Co-CEO Juliana Komel. "From the beginning, our objective has been to expand access in Brazil to quality-controlled Cannabis Products manufactured in accordance with the applicable regulatory requirements. MediPharm’s manufacturing capabilities, ANVISA GMP-certified facility and technical expertise were important throughout the regulatory process."

The Canadian Export Pivot: Moving Beyond Saturated Markets

From a broader business perspective, MediPharm’s Brazilian expansion is emblematic of a necessary pivot for Canadian licensed producers. The domestic Canadian market, while mature, is heavily saturated. Retail price compression for adult-use products has decimated the balance sheets of companies that over-indexed on massive greenhouse cultivation.

The survivors of the "green rush" are those who recognized early that the future of high-margin cannabis lies in active pharmaceutical ingredients (APIs) and finished, export-ready medical dosages. MediPharm has aggressively pursued this path, securing not just Health Canada and ANVISA licenses, but also EU-GMP certification and compliance with Australia’s Therapeutic Goods Administration.

"The companies winning right now are the ones treating cannabis like a traditional pharmaceutical supply chain, not an agricultural commodity," noted a Toronto-based healthcare equities analyst familiar with the international cannabis trade. "If you can pass an ANVISA audit or an EU-GMP inspection, you suddenly have access to tens of millions of patients in jurisdictions where domestic production simply cannot meet pharmaceutical standards. It transforms a company from a local farmer into a global biotech supplier."

This strategic positioning was further bolstered by MediPharm’s 2023 acquisition of VIVO Cannabis Inc., which expanded its reach into Germany and Australia. The Brazilian launch is the next logical step in diversifying revenue away from the volatile North American retail sector.

Navigating an Evolving Competitive Landscape

Despite the high barriers to entry, MediPharm and Alko are not stepping into a vacuum. As of late 2025, ANVISA had authorized roughly 50 cannabis products, with 14 holding full formal registration. MediPharm’s 100 mg/mL full-spectrum oral drop enters a competitive arena featuring established players like Promediol, Zion Medpharma, and domestic pharmaceutical giants like Prati-Donaduzzi.

The regulatory environment is also dynamic. In February 2026, ANVISA approved measures allowing pharmacies to prepare and sell registered oral and sublingual CBD products, and expanded the therapeutic uses of higher-THC products for patients with severe, debilitating illnesses. Concurrently, the Brazilian government is reviewing regulations to govern domestic cannabis cultivation for medical and research purposes, following a landmark ruling by the Superior Court of Justice.

While domestic cultivation could eventually introduce cheaper local inputs, the strict requirement for pharmaceutical-grade extraction, formulation, and stability testing means that high-tech manufacturers like MediPharm will retain a significant advantage. The transition from raw plant material to a precise, shelf-stable, ANVISA-approved medicine requires millions in capital expenditure and years of technical expertise—assets that cannot be easily replicated by newly licensed domestic farms.

For now, MediPharm Labs has successfully planted its flag in Latin America’s most critical market. As the global cannabis economy continues to splinter into distinct adult-use and pharmaceutical segments, the companies capable of speaking the language of international health regulators are the ones poised to capture the bottom-line benefits.